Eupraxia Pharmaceuticals Inc. (EPRX) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Eupraxia Pharmaceuticals Inc. (EPRX) Earnings Overview
As of June 23, 2026, Eupraxia Pharmaceuticals Inc. (EPRX) reported trailing twelve-month net income of -$47M, reflecting -38.2% year-over-year growth. The company earned $-0.84 per diluted share over the past four quarters.
Looking at the long-term picture, EPRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2020.
Eupraxia Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$129M net income, -341.5% margin), IRWD ($102M net income, 8.1% margin), PTGX (-$115M net income, -282.8% margin), EPRX has comparable earnings metrics. Compare EPRX vs PACB →
EPRX Earnings vs Peers
Earnings metrics vs comparable public companies
EPRX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$54M | -46.9% | -$54M | $-1.05 | - | - |
| 2024 | -$37M | -30.0% | -$39M | $-0.76 | - | - |
| 2023 | -$28M | -52.6% | -$28M | $-1.17 | - | - |
| 2022 | -$18M | -2.5% | -$18M | $-0.96 | - | - |
| 2021 | -$18M | -350.1% | -$15M | $-1.61 | - | - |
| 2020 | -$4M | +45.7% | -$2M | $-0.31 | - | - |
| 2019 | -$7M | +44.1% | -$7M | $-0.56 | - | - |
| 2018 | -$13M | -201.1% | -$12M | $-1.03 | - | - |
| 2017 | -$4M | - | -$5M | $-0.34 | - | - |
Download Data
Export EPRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EPRX — Frequently Asked Questions
Quick answers to the most common questions about buying EPRX stock.
What is EPRX earnings per share (EPS)?
EPRX trailing twelve-month (TTM) diluted EPS is $-0.84, reflecting -38.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Eupraxia Pharmaceuticals Inc.'s net income?
Eupraxia Pharmaceuticals Inc. (EPRX) trailing twelve-month net income is $-47M as of 2025. Earnings declined -38.2% year-over-year.
Is EPRX profitable?
EPRX is not currently profitable on a TTM basis, reporting a net loss of $-47M. Net margin is N/A. Investors should monitor for a return to profitability.
What is EPRX's earnings growth rate?
EPRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are EPRX's profit margins?
Eupraxia Pharmaceuticals Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -95.9%.
Is EPRX growing earnings?
EPRX earnings are declining — EPS fell -38.2% year-over-year. TTM net income dropped to $-47M. This contrasts with the 5-year CAGR of N/A.
What was EPRX's best earnings year?
Eupraxia Pharmaceuticals Inc.'s highest annual net income on record is $-4M, achieved in fiscal year 2020. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were EPRX's earnings last quarter?
EPRX's most recent reported quarter was Q1 2026. Net income was $-12M with diluted EPS of $-0.23. For a full breakdown of all quarters, see the quarterly earnings table on this page.